Park, Sook Ryun

Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial

Noh, S. H., Park, S. R., Yang, H.-K., Chung, H. C., Chung, I.-J., Kim, S.-W., Kim, H.-H., Choi, J.-H., Kim, H.-K., Yu, W., et al. (2014) · The Lancet Oncology

Gastric Cancer Management and OutcomesIntraperitoneal and Appendiceal Malignancies

Cited by 1,049

Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors

Jeong, W., Rapisarda, A., Park, S. R., Kinders, R. J., Chen, A., Melillo, G., Turkbey, B., Steinberg, S. M., Choyke, P., Doroshow, J. H., et al. (2014) · Cancer Chemotherapy and Pharmacology

Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Cited by 159

Abstract 3616: Validation and fitness testing of a quantitative immunoassay for HIF1α in biopsy specimens

Park, S. R., Kinders, R. J., Khin, S., Hollingshead, M., Parchment, R. E., Tomaszewski, J. E., & Doroshow, J. H. (2012) · Cancer Research

Cancer, Hypoxia, and MetabolismClinical Laboratory Practices and Quality Control

Cited by 1